DONG HA, Vietnam, 26 février 2024 /PRNewswire/ — Electric Wind Power (« l’entreprise », SHA:688660), une filiale de Shanghai Electric (SEHK:2727, SSE:601727), également le premier fabricant chinois d’équipements éoliens terrestres et l’un des plus grands fabricants chinois d’équipements…
Month: February 2024
B. Riley Securities to Host Radiopharma Investor Conference in New York on March 1, 2024
LOS ANGELES, Feb. 26, 2024 /PRNewswire/ — B. Riley Securities, a leading middle market brokerage and investment bank, and subsidiary of B. Riley Financial (Nasdaq: RILY) (“B. Riley”), today announced that it will host a Radiopharma Investor Conference on March 1, 2024 in New York. This…
B. Riley Securities to Host Radiopharma Investor Conference in New York on March 1, 2024
LOS ANGELES, Feb. 26, 2024 /PRNewswire/ — B. Riley Securities, a leading middle market brokerage and investment bank, and subsidiary of B. Riley Financial (Nasdaq: RILY) (“B. Riley”), today announced that it will host a Radiopharma Investor Conference on March 1, 2024 in New York. This…
Marvell Open Sources OCTEON 10 ML/AI Accelerator Software to Optimize 5G RAN Networks
Adding OCTEON® 10 processor to Linux Foundation’s Datapath Developer Kit and the Apache device library provides ML model developers standardized API access to the chip’s ML/AI acceleration engine. Improves the performance of 5G RAN networks by enabling OEMs and operators, such as Nokia…
Marvell Open Sources OCTEON 10 ML/AI Accelerator Software to Optimize 5G RAN Networks
Adding OCTEON® 10 processor to Linux Foundation’s Datapath Developer Kit and the Apache device library provides ML model developers standardized API access to the chip’s ML/AI acceleration engine. Improves the performance of 5G RAN networks by enabling OEMs and operators, such as Nokia…
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
– Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm patients none of whom survived even one year – Unprecedented 100% BMT access and…
Actinium Announces Iomab-B Markedly Increases Long Term Survival in Patients 65 Years or Older with Active Relapsed or Refractory AML in the Phase 3 SIERRA Trial at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® and CIBMTR®
– Active relapsed or refractory AML patients 65+ years receiving an Iomab-B led Bone Marrow Transplant (BMT) achieved significant improvement in survival at one and two years compared to control arm patients none of whom survived even one year – Unprecedented 100% BMT access and…
GeminiBio launches human serum AB product for global cell therapy market
WEST SACRAMENTO, Calif., Feb. 26, 2024 /PRNewswire/ — Gemini Bioproducts, LLC (“GeminiBio”), a leading supplier of cell culture reagents and process liquids, a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, today…
GeminiBio launches human serum AB product for global cell therapy market
WEST SACRAMENTO, Calif., Feb. 26, 2024 /PRNewswire/ — Gemini Bioproducts, LLC (“GeminiBio”), a leading supplier of cell culture reagents and process liquids, a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a Florida-based healthcare private equity firm, today…
Spyre Therapeutics to Participate in the 44th Annual TD Cowen Health Care Conference
WALTHAM, Mass., Feb. 26, 2024 /PRNewswire/ — Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a development-stage biotechnology company advancing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches for the treatment…
